↓ Skip to main content

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

Overview of attention for article published in BMC Research Notes, September 2016
Altmetric Badge

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
Published in
BMC Research Notes, September 2016
DOI 10.1186/s13104-016-2256-3
Pubmed ID
Authors

Stefan Vallo, Martin Michaelis, Kilian M. Gust, Peter C. Black, Florian Rothweiler, Hans-Michael Kvasnicka, Roman A. Blaheta, Maximilian P. Brandt, Felix Wezel, Axel Haferkamp, Jindrich Cinatl

Abstract

Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers. Since there are controversial reports about the role of Src in bladder cancer, we evaluated the efficacy of the Src kinase inhibitor dasatinib in the urothelial bladder cancer cell line RT112 and its gemcitabine-resistant sub-line RT112(r)GEMCI(20) in vitro and in vivo. RT112 urothelial cancer cells were adapted to growth in the presence of 20 ng/ml gemcitabine (RT112(r)GEMCI(20)) by continuous cultivation at increasing drug concentrations. Cell viability was determined by MTT assay, cell growth kinetics were determined by cell count, protein levels were measured by western blot, and cell migration was evaluated by scratch assays. In vivo tumor growth was tested in a murine orthotopic xenograft model using bioluminescent imaging. Dasatinib exerted similar effects on Src signaling in RT112 and RT112(r)GEMCI(20) cells but RT112(r)GEMCI(20) cells were less sensitive to dasatinib-induced anti-cancer effects (half maximal inhibitory concentration (IC50) of dasatinib in RT112 cells: 349.2 ± 67.2 nM; IC50 of dasatinib in RT112(r)GEMCI(20) cells: 1081.1 ± 239.2 nM). Dasatinib inhibited migration of chemo-naive and gemcitabine-resistant cells. Most strikingly, dasatinib treatment reduced RT112 tumor growth and muscle invasion in orthotopic xenografts, while it was associated with increased size and muscle-invasive growth in RT112(r)GEMCI(20) tumors. Dasatinib should be considered with care for the treatment of urothelial cancer, in particular for therapy-refractory cases.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 20%
Student > Postgraduate 2 13%
Professor 2 13%
Researcher 2 13%
Unspecified 1 7%
Other 1 7%
Unknown 4 27%
Readers by discipline Count As %
Medicine and Dentistry 8 53%
Biochemistry, Genetics and Molecular Biology 2 13%
Unspecified 1 7%
Unknown 4 27%